Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).Jeffrey Clarke, Edward F. Patz, Guru Sonpavde et al.|Journal of Clinical Oncology|2023Cited by 4
Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.Hirva Mamdani, Edward F. Patz, Jeffrey Clarke et al.|Journal of Clinical Oncology|2024Cited by 2
699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC)Jeffrey Clarke, George R. Simon, Thomas E. Stinchcombe et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1